Contrasting Agios Pharmaceuticals (NASDAQ:AGIO) & TuHURA Biosciences (NASDAQ:HURA)

TuHURA Biosciences (NASDAQ:HURA) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.

Analyst Ratings

This is a breakdown of recent recommendations for TuHURA Biosciences and Agios Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1	0	2	1	2.75
Agios Pharmaceuticals	1	4	6	0	2.45

TuHURA Biosciences currently has a consensus price target of $9.00, indicating a potential upside of 1,224.89%. Agios Pharmaceuticals has a consensus price target of $39.44, indicating a potential upside of 37.63%. Given TuHURA Biosciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe TuHURA Biosciences is more favorable than Agios Pharmaceuticals.

Insider & Institutional Ownership

0.6% of TuHURA Biosciences shares are held by institutional investors. 0.2% of TuHURA Biosciences shares are held by company insiders. Comparatively, 4.3% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares TuHURA Biosciences and Agios Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-196.68%	-123.41%
Agios Pharmaceuticals	-895.86%	-28.35%	-26.42%

Risk & Volatility

TuHURA Biosciences has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Valuation and Earnings

This table compares TuHURA Biosciences and Agios Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$21.68 million	($0.50)	-1.36
Agios Pharmaceuticals	$36.50 million	45.79	$673.72 million	($7.00)	-4.09

Agios Pharmaceuticals has higher revenue and earnings than TuHURA Biosciences. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

About TuHURA Biosciences

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.